Vaxcyte Total Assets from 2010 to 2025

PCVX Stock

USD 73.17 1.49 2.00%

Vaxcyte Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets are likely to outpace its year average in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-12-31

Previous Quarter

3.6 B

Current Value

3.5 B

Quarterly Volatility

1 B

Covid

Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.

Check out the analysis of Vaxcyte Correlation against competitors.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Total Assets Growth Pattern

Below is the plot of the Total Assets of Vaxcyte over the last few years. Total assets refers to the total amount of Vaxcyte assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vaxcyte books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Vaxcyte's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 3.51 B

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Vaxcyte Total Assets Regression Statistics

	Arithmetic Mean	673,937,994
	Geometric Mean	150,064,688
	Coefficient Of Variation	179.42
	Mean Deviation	864,568,116
	Median	65,698,000
	Standard Deviation	1,209,170,888
	Sample Variance	1462094.2T
	Range	3.6B
	R-Value	0.74
	Mean Square Error	713282.8T
	R-Squared	0.54
	Significance	0
	Slope	187,439,827
	Total Sum of Squares	21931413.6T

Vaxcyte Total Assets History

	2025	3.7 B
	2024	3.5 B
	2023	1.4 B
	2022	1 B
	2021	324.3 M
	2020	392.8 M
	2019	65.7 M

Other Fundumenentals of Vaxcyte

Intangibles To Total Assets

Vaxcyte Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.89	-0.97	0.93	-0.62	-0.62	0.77	0.63	0.98	0.92	0.79	-0.55	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Total Stockholder Equity	1.0		0.89	-0.97	0.93	-0.6	-0.6	0.77	0.6	0.98	0.92	0.79	-0.53	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Net Tangible Assets	0.89	0.89		-0.94	0.81	-0.76	-0.76	0.92	0.58	0.96	0.98	0.9	-0.72	-0.78	0.9	0.94	0.96	0.74	0.9	0.88
Retained Earnings	-0.97	-0.97	-0.94		-0.89	0.71	0.71	-0.84	-0.7	-0.99	-0.97	-0.87	0.65	0.56	-0.97	-0.89	-0.98	-0.55	-0.98	-0.83
Accounts Payable	0.93	0.93	0.81	-0.89		-0.67	-0.67	0.79	0.58	0.9	0.88	0.66	-0.6	-0.49	0.93	0.76	0.9	0.54	0.83	0.59
Long Term Debt	-0.62	-0.6	-0.76	0.71	-0.67		1.0	-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Long Term Debt Total	-0.62	-0.6	-0.76	0.71	-0.67	1.0		-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Capital Surpluse	0.77	0.77	0.92	-0.84	0.79	-0.88	-0.88		0.51	0.85	0.95	0.9	-0.85	-0.72	0.78	0.93	0.84	0.91	0.79	0.88
Total Liab	0.63	0.6	0.58	-0.7	0.58	-0.68	-0.68	0.51		0.65	0.62	0.54	-0.65	-0.31	0.62	0.64	0.63	0.28	0.69	0.56
Total Current Assets	0.98	0.98	0.96	-0.99	0.9	-0.71	-0.71	0.85	0.65		0.97	0.85	-0.65	-0.65	0.98	0.88	1.0	0.59	0.95	0.81
Common Stock	0.92	0.92	0.98	-0.97	0.88	-0.8	-0.8	0.95	0.62	0.97		0.91	-0.76	-0.69	0.93	0.94	0.97	0.74	0.93	0.88
Property Plant Equipment	0.79	0.79	0.9	-0.87	0.66	-0.77	-0.77	0.9	0.54	0.85	0.91		-0.74	-0.6	0.8	0.88	0.85	0.75	0.85	0.98
Current Deferred Revenue	-0.55	-0.53	-0.72	0.65	-0.6	1.0	1.0	-0.85	-0.65	-0.65	-0.76	-0.74		0.65	-0.56	-0.79	-0.63	-0.83	-0.6	-0.74
Net Debt	-0.5	-0.5	-0.78	0.56	-0.49	0.65	0.65	-0.72	-0.31	-0.65	-0.69	-0.6	0.65		-0.51	-0.72	-0.65	-0.78	-0.45	-0.63
Net Invested Capital	1.0	1.0	0.9	-0.97	0.93	-0.63	-0.63	0.78	0.62	0.98	0.93	0.8	-0.56	-0.51		0.81	0.98	0.48	0.94	0.74
Capital Stock	0.8	0.8	0.94	-0.89	0.76	-0.81	-0.81	0.93	0.64	0.88	0.94	0.88	-0.79	-0.72	0.81		0.87	0.78	0.84	0.92
Net Working Capital	0.98	0.98	0.96	-0.98	0.9	-0.69	-0.69	0.84	0.63	1.0	0.97	0.85	-0.63	-0.65	0.98	0.87		0.58	0.94	0.81
Short Term Debt	0.46	0.46	0.74	-0.55	0.54	-0.83	-0.83	0.91	0.28	0.59	0.74	0.75	-0.83	-0.78	0.48	0.78	0.58		0.48	0.76
Net Receivables	0.94	0.94	0.9	-0.98	0.83	-0.65	-0.65	0.79	0.69	0.95	0.93	0.85	-0.6	-0.45	0.94	0.84	0.94	0.48		0.81
Deferred Long Term Liab	0.73	0.73	0.88	-0.83	0.59	-0.76	-0.76	0.88	0.56	0.81	0.88	0.98	-0.74	-0.63	0.74	0.92	0.81	0.76	0.81

Click cells to compare fundamentals

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	3.5 B	3.7 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC